How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,258 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Time course of changes in tear meniscus radius and blink rate after instillation of artificial tears. (Full text)

-guar and glycol (SYS) or saline (SAL). A dose of 35 μL was applied in one eye in a randomized order with a washout period between each drop.For SAL, compared to baseline TMR (0.33 ± 0.08 mm), TMR significantly increased with drop instillation (1.55 ± 0.69 mm) and at 1 minute (0.66 ± 0.36 mm; P < 0.05), but returned to baseline after 5 minutes. For SYS, TMR (0.32 ± 0.07 mm) remained significantly increased after application (1.62 ± 0.81 mm), and at 1 minute (0.81 ± 0.43 mm) and 5 minutes (0.39 (...) ± 0.08 mm; P < 0.05). Compared to baseline BR with SAL (14.8 ± 7.7) and SYS (14.9 ± 9.4), values were significantly increased upon drop instillation (22.5 ± 11.8; 21.3 ± 11.8; P < 0.05), but returned to baseline after 1 minute. Dry eye symptoms were correlated with baseline BR (r = 0.550, P = 0.008).Results indicate that PDM can detect changes in TMR following instillation of artificial tears. Difference in residence time reflects the different viscosity of each drop. An overload with a large drop

2014 Investigative Ophthalmology & Visual Science PubMed

162. Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Intervention/treatment Experimental: AGN-195263 Drug: AGN-195263 1 drop of AGN-195263 will be instilled in each eye twice daily. Placebo Comparator: Vehicle Drug: Vehicle 1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily. Outcome Measures Go to Primary Outcome Measures : Overall Ocular Discomfort Score (0 to 4 Scale; 0=None, 4=Very Severe) [ Time Frame: 6 month visit ] The overall ocular discomfort will be assessed on a questionnaire using a 0 to 4 scale on which 0=none, 1 (...) Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical

2016 Clinical Trials

163. Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

. Information provided by (Responsible Party): Kala Pharmaceuticals, Inc. Study Details Study Description Go to Brief Summary: The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID). Condition or disease Intervention/treatment Phase Dry Eye (...) of the Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02819284 Sponsors and Collaborators Kala Pharmaceuticals, Inc. More

2016 Clinical Trials

164. Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements. Drug: Phenylephrine 2.5% Instilling phenylephrine 2.5% eye drop Outcome Measures Go to Primary Outcome Measures : Change in episcleral venous pressure [ Time Frame: baseline, 60 minutes ] Comparison using a two-sided t-test Secondary Outcome Measures : Change in intraocular pressure [ Time Frame: baseline, 60 minutes ] Comparison using a two-sided t-test Eligibility Criteria Go to Information (...) Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Topical

2016 Clinical Trials

165. Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Intervention/treatment Experimental: AGN-195263 Drug: AGN-195263 1 drop of AGN-195263 will be instilled in each eye twice daily. Placebo Comparator: Vehicle Drug: Vehicle 1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily. Outcome Measures Go to Primary Outcome Measures : Overall Ocular Discomfort Score (0 to 4 Scale; 0=None, 4=Very Severe) [ Time Frame: 6 month visit ] The overall ocular discomfort will be assessed on a questionnaire using a 0 to 4 scale on which 0=none, 1 (...) Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical

2016 Clinical Trials

166. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

for the Treatment of Dry Eye : ARISE-2 Actual Study Start Date : November 2016 Actual Primary Completion Date : September 2017 Actual Study Completion Date : March 2018 Arms and Interventions Go to Arm Intervention/treatment Experimental: RGN-259 RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4 Drug: RGN-259 A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days Other Names: Tβ4 Thymosin Beta 4 Placebo (...) reported history of dry eye for at least 6 months Have a history of use or desire to use eye drops for dry eye symptoms within 6 months Exclusion Criteria: Have any clinically significant slit-lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters; Be diagnosed with an ongoing ocular infection

2016 Clinical Trials

167. Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome

: Allergan Pharmaceuticals, Ireland Active Comparator: Experimental: Patients with dry eye syndrome 3 40 Patients with dry eye syndrome Device: Systane Ultra Eye Drops Manufacturer: Alcon Pharma GmbH Outcome Measures Go to Primary Outcome Measures : Change in tear film thickness as measured with Optical Coherence Tomography (OCT) [ Time Frame: 10 weeks; at baseline, 10 minutes, 20 minutes, 40 minutes, 60 minutes, 120 minutes and 240 minutes after instillation of eye drops as well as 4 weeks and 8 weeks (...) . The aim of the present study is to assess the influence on tear film thickness of three different formulations of topical lubricants, in particular Thealoz Duo® Eye Drops, Optive® Eye Drops and Systane Ultra® Eye Drops in patients with moderate to severe dry eye disease. In addition, standard tests for dry eye syndrome, such as the ocular surface disease index (OSDI©), Schirmer I test, corneal fluorescein staining and determination of tear break up time (BUT) will be performed to compare the product

2016 Clinical Trials

168. Difference in the Frequency of Use of Lachrymal Substitutes in Patients With Moderate to Severe Dry Eye Syndrome

during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days Other Name: Intervention 1 Device: Thealoz Duo gel Thealoz Duo gel during the day and at night for 7 days Other Name: Intervention 2 Outcome Measures Go to Primary Outcome Measures : Number of drops of Thealoz Duo® eye drops and Thealoz Duo® gel instilled during the day (patient diary) [ Time Frame: 4 weeks ] Number of drops of Thealoz Duo® eye drops and Thealoz Duo® gel instilled during the day during the observation (...) is usually reached by the use of artificial tears during the day. Nighttime relief is often achieved by substances known to be more adhesive to the ocular surface, such as gels. Condition or disease Intervention/treatment Phase Dry Eye Syndromes Device: Thealoz Duo eye drops and Thealoz Duo gel Device: Thealoz Duo gel Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 45 participants Allocation: Randomized Intervention

2016 Clinical Trials

169. Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome

and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : Dry Eye Symptoms (SPEED Questionnaire) [ Time Frame: Day 0 ] Secondary Outcome Measures : Non-invasive Tear Break-up Time (NIKBUT) [ Time Frame: Day 0 ] Conjunctival Redness Grading with Oculus Keratograph 5M [ Time Frame: Day 0 ] Tear collection from Schirmers strip [ Time Frame: Day 0 ] To profile immune cells with EyePRIM membrane [ Time Frame: Day 0 ] Patients will be instilled with 1 drop of local anaesthetic. Conjunctival cells (...) Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Exploring Immune

2016 Clinical Trials

170. To Evaluate Eye Installation-Tear Free

091 Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule. Drug: SPF 50 Y49 091 (BAY 987516) 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye. Other: J & J baby shampoo, X46 046 (control) 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye. Experimental: SPF 50 X15 158 (...) Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule. Drug: SPF 50 X15 158 (BAY 987516) 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye. Other: J & J baby shampoo, X46 046 (control) 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye. Experimental: SPF 50 X15 160 Subjects

2016 Clinical Trials

171. Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

. Study Details Study Description Go to Brief Summary: The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID). Condition or disease Intervention/treatment Phase Dry Eye Syndromes Keratoconjunctivitis Sicca Drug: KPI-121 0.25% Ophthalmic (...) to successfully instill eye drops. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02813265 Sponsors and Collaborators Kala Pharmaceuticals, Inc. More Information Go to Layout table for additonal information Responsible Party: Kala Pharmaceuticals, Inc

2016 Clinical Trials

172. Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

Study Details Study Description Go to Brief Summary: To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months. Condition or disease Intervention/treatment Phase Dry Eye Drug: Lifitegrast Phase 4 Detailed Description: A longitudinal, single-arm, prospective study will recruit up to 30 subjects with moderate to severe dry eye disease. Subjects will be >18 years of age, diagnosed (...) with moderate to severe dry eye (tear osmolarity > 320 mOsm/L and Visual Analog Scale (VAS) score > 40), willing to adhere to twice daily dosing (BID) and follow up visit schedule, have no history of ocular pathology / degeneration / allergy, not on any T-cell modulatory therapy, not have instilled any artificial tears within 2 hours of study visit, and not participating in any concurrent clinical trials. All subjects will complete an informed consent form indicating their voluntary participation

2016 Clinical Trials

173. Effect of different lubricant eye gels on tear film thickness as measured with ultrahigh-resolution optical coherence tomography. (PubMed)

unpreserved trehalose 3% + hyaluronic acid 0.15% (TH), hyaluronic acid 0.2% (HA) or polyethylene glycol 0.4% + propylene glycol 0.3% (PP) eye drops. In total, 60 patients were included and TFT was measured using a custom-built UHR-OCT system.The mean TFT at baseline was 3.5 ± 0.7 μm. There was a significant difference in the time-course of TFT between the three groups (p = 0.001 between groups). Ten minutes after instillation, TFT increased by 155.8 ± 86.6%, 65.7 ± 71.5% and 33.4 ± 19.6% in the PP, TH (...) Effect of different lubricant eye gels on tear film thickness as measured with ultrahigh-resolution optical coherence tomography. To compare the effect of a single drop of different lubricant eye gels on tear film thickness (TFT) as measured with ultrahigh-resolution optical coherence tomography (UHR-OCT) in patients with mild-to-moderate dry eye disease (DED).The study followed a randomized, single-masked, observer-blinded parallel group design. Patients received a single dose of either

2016 Acta ophthalmologica

174. Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study. (Full text)

Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study. The purpose of this study is to assess the effectiveness and tolerability of a dietary supplement with a combination of omega-3 fatty acids and antioxidants on dry eye symptoms caused by chronic instillation of antihypertensive eye drops in patients with glaucoma.A total of 1,255 patients with glaucoma and dry eye symptoms related to antiglaucoma topical medication (...) eye symptoms were statistically significant as compared to noncompliant patients.Dietary supplementation with Brudypio(®) may be a clinically valuable additional option for the treatment of dry eye syndrome in patients with glaucoma using antiglaucoma eye drops. These results require confirmation with an appropriately designed randomized controlled study.

2016 Clinical ophthalmology (Auckland, N.Z.) PubMed

175. The leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride–induced murine dry eye model (Full text)

treatment. Preservative-free eye drops were instilled in the positive-control group. The tear secretion volume (Schirmer's test), tear break-up time (BUT), and fluorescein score were measured on the ocular surface. BAC-induced corneal damage was tested with hematoxylin-eosin staining. Moreover, apoptotic cell death in the corneal epithelial layer was investigated with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The protein expression level of interleukin (...) The leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride–induced murine dry eye model In this study, the beneficial effects of the oral administration of ethanol extract of Diospyros kaki (EEDK) were tested on a mouse dry eye model induced by benzalkonium chloride (BAC).A solution of 0.2% BAC was administered topically to mouse eyes for 14 days, twice daily, to induce dry eye. Various concentrations of EEDK were administrated daily by oral gavage for 14 days after BAC

2016 Molecular vision PubMed

176. Dry Eye

Contacts) Consider eye lubricants (e.g. lacrilube) for moderate symptoms (esp. at night), but may blur vision Avoid agents with (e.g. Visine original) Consider s and other agents in refractory to other measures (Restasis) ( ) ( ) Other options in refractory cases Lifitegrast (Xiidra) function-associated antigen-1 (LFA-1) antagonist ophthalmic solution One drop instilled every 12 hours Expensive (>$400/month), with risk of eye irritation, altered es must be out of eye for installation for at least 15 (...) . Epidemiology As many as 30% of over age 50 years old complain of dry, irritated eyes III. Causes Decreased blinking with prolonged reading or driving Chronic exposure to dry, dusty conditions See (e.g. s, s, ) IV. Management ral measures Room humidifiers Take computer breaks Protect eyes from fan Avoid drying, s ( s, s, s) Artificial tears or ointments Preservative-free solutions are preferred (e.g. Refresh Plus), esp. if used more than 4x/day users may try rewetting drops (e.g. Renu rewetting, Blink

2018 FP Notebook

177. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. (Full text)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. To evaluate the 1-year safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease compared with placebo.SONATA (Safety Of a 5.0% coNcentrATion of lifitegrAst ophthalmic solution) was a multicenter, randomized, prospective, double-masked, placebo-controlled phase 3 study (NCT01636206). Adults (≥18 years) with dry eye disease (Schirmer (...) test score ≥1 and ≤10 mm; corneal staining score ≥2.0) were randomized 2:1 to lifitegrast ophthalmic solution 5.0% or placebo twice daily for 360 days. The primary objective was percentage and severity of treatment-emergent adverse events (TEAEs). Secondary objectives were ocular safety measures: corneal fluorescein staining, drop comfort, best-corrected visual acuity, slit-lamp biomicroscopy, and intraocular pressure over 7 visits. Exploratory objectives included concentration of lifitegrast

2016 Cornea PubMed

178. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. (PubMed)

Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. The SANSIKA study was conducted to assess the treatment effect of 0.1% cyclosporine A cationic emulsion (CsA CE) eye drops on signs and symptoms of patients with severe dry eye disease (DED).This was a multicenter, randomized, double-masked, 2-parallel-arm, 6-month phase III study with a 6-month open-label treatment safety follow-up. Patients with severe DED (...) CFS change from baseline to month 6 (-1.764 vs -1.418, p = 0.037). There was a reduction in ocular surface inflammation assessed by human leukocyte antigen DR expression in favor of CsA CE at month 6 (p = 0.021). The mean OSDI change from baseline was -13.6 with CsA CE and -14.1 with vehicle at month 6 (p = 0.858). The main adverse event was instillation site pain (29.2% vs 8.9% in the CsA CE and vehicle groups, respectively), and it was mostly mild.CsA CE was well-tolerated and effective

2016 European journal of ophthalmology

179. Pupil dilation using drops vs gel: a comparative study (Full text)

Pupil dilation using drops vs gel: a comparative study To compare the efficacy in pupil dilation and degree of discomfort between topical instillation of mydriatic drops and gel.The study included 60 patients with no previous ocular history of trauma and surgery. One eye was dilated with two drops (tropicamide 0.5% and phenylephrine 10%), and the other with one drop of gel (tropicamide 0.5%+phenylephrine 5%). Pupil size was measured by a Colvard pupillometer at baseline and 5, 15, 30, and 45 (...)  min following instillation. Pain upon instillation was measured by visual analog scale (VAS).There was no difference in pupil size at baseline. Use of the gel achieved greater mydriasis than drops (P=0.01), and was also associated with lower pain scores (P=0.003). In diabetic patients, pupil size was smaller at baseline and following instillation of drops and gel. Use of the gel achieved an even greater degree of pupil dilation in this subset of patients than drops (P=0.019).Gel formulation

2015 Eye PubMed

180. Proficiency of Eye Drop Instillation in Postoperative Cataract Patients in Ghana

Proficiency of Eye Drop Instillation in Postoperative Cataract Patients in Ghana Proficiency of Eye Drop Instillation in Postoperative Cataract Patients in Ghana - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Proficiency of Eye Drop Instillation in Postoperative Cataract Patients in Ghana The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01181752 Recruitment Status : Unknown Verified February 2012 by University of British Columbia. Recruitment status was: Not yet recruiting First Posted : August 13

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>